Current studies focus on cellular and humoral immunity induced by novel SARS-CoV-2 vaccines. Non-responders to vaccinations are not uncommonly encountered in clinical medicine (e.g. in the field of hepatitis B). Whereas vaccine-induced humoral immunity against SARS-CoV-2 is compromised by emerging Variants of Concern (VOCs), cellular immunity against SARS-CoV-2 is emerging as resilient against VOCs. Thus commercially available test kits for diagnostic laboratories designed to evaluate cellular immune responses to SARS-CoV-2 are urgently needed. Here we evaluated the novel QuantiFERON SARS-CoV-2 assay (Qiagen) measuring INF-ɣ release induced by two spike-derived peptide pools (Ag1 and Ag2) in a cohort of health care workers vaccinated with the mRNA-1273 vaccine and confirmed humoral response. Our study indicates the usefulness of this novel assay for routine laboratories to evaluate cellular immunity against SARS-CoV-2 in response to mRNA-1273 vaccination.

目前的研究主要集中在新型 SARS-CoV-2 疫苗诱导的细胞和体液免疫上。对疫苗接种无反应的人在临床医学中并不少见（例如在乙型肝炎领域）。尽管疫苗诱导的针对 SARS-CoV-2 的体液免疫受到新出现的关注变体 (VOC) 的影响，但针对 SARS-CoV-2 的细胞免疫正逐渐成为对 VOC 的弹性免疫。因此，迫切需要用于诊断实验室的市售检测试剂盒，旨在评估对 SARS-CoV-2 的细胞免疫反应。在这里，我们评估了新型 QuantiFERON SARS-CoV-2 测定法 (Qiagen)，它测量了一组接种了 mRNA-1273 疫苗的医护人员中由两个尖峰衍生肽池（Ag1 和 Ag2）诱导的 INF-ɣ 释放，并确认体液回复。